Exhibit 99.1
Form 51-102F3
Material Change Report
Item 1 Name and Address of Company
Titan Medical Inc. (the “Company” or “Titan”)
170
University Avenue
Suite 1000
Toronto, Ontario
M5H 3B3
Item 2 Date of Material Change
March 5, 2019 and March 6, 2019.
Item 3 News Release
The press releases attached as Schedule “A” and Schedule “B” were disseminated through Marketwired on March 5, 2019 and March 6, 2019 with respect to the material changes.
Item 4 Summary of Material Change
On March 5, 2019, the Company filed a preliminary short-form prospectus dated March 5, 2019 with securities regulators in Ontario, British Columbia and Alberta and a corresponding registration statement on Form F-10 with the United States Securities and Exchange Commission, with respect to its offering of units (the “Offering”) for minimum gross proceeds at US$20,000,000 and the maximum gross proceeds at US$25,000,000.
On March 6, 2019, the Company set the price of the Offering at US$3.40 per unit and determined that each unit would consist of one common share and one common share purchase warrant and that the warrants would each be exercisable for one common share at a price of US$4.00 for a period of 5 years following the closing of the Offering.
Item 5 Full Description of Material Change
5.1 Full Description of Material Change
Please see the press releases attached as Schedule “A” and Schedule “B”.
5.2 Disclosure for Restructuring Transactions
Not applicable.
Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102
Not applicable.
Item 7 Omitted Information
Not applicable.
Item 8 Executive Officer
The following executive officer is knowledgeable about the material changes and may be contacted about this report:
Stephen Randall
Chief Financial Officer
(416) 548-7522 (ext. 152)
Email: stephen@titanmedicalinc.com
Website: www.titanmedicalinc.com
Item 9 Date of Report
March 6, 2019.
Schedule “A”
[See Attached]
Schedule “B”
[See Attached]